$XBIT
XBiotech Inc

2019 Q3 Form 10-Q Financial Statement

#000117184319005378 Filed on August 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.580M $1.310M $1.670M
YoY Change 33.9% -21.56% -27.07%
% of Gross Profit
Research & Development $4.533M $4.693M $3.949M
YoY Change 15.05% 18.84% -46.63%
% of Gross Profit
Depreciation & Amortization $600.0K $600.0K $610.0K
YoY Change -3.23% -1.64% 110.34%
% of Gross Profit
Operating Expenses $6.111M $6.006M $5.621M
YoY Change 19.47% 6.85% -41.98%
Operating Profit -$6.111M -$6.006M -$5.621M
YoY Change 19.47% 6.85% -41.98%
Interest Expense -$40.00K $150.0K -$290.0K
YoY Change -166.67% -151.72% -151.79%
% of Operating Profit
Other Income/Expense, Net -$39.00K $154.0K -$286.0K
YoY Change -160.94% -153.85% -151.53%
Pretax Income -$6.150M -$5.852M -$5.910M
YoY Change 21.78% -0.98% -35.27%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.150M -$5.852M -$5.907M
YoY Change 21.76% -0.93% -35.32%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.16
Diluted Earnings Per Share -$0.15 -$0.16 -$165.0K
COMMON SHARES
Basic Shares Outstanding 41.01M 36.11M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.30M $44.90M $24.80M
YoY Change 93.75% 81.05% -45.97%
Cash & Equivalents $40.34M $44.92M $24.85M
Short-Term Investments
Other Short-Term Assets $600.0K $700.0K $900.0K
YoY Change 20.0% -22.22% -35.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.91M $45.60M $25.77M
YoY Change 92.02% 76.97% -45.53%
LONG-TERM ASSETS
Property, Plant & Equipment $25.73M $26.28M $28.52M
YoY Change -7.9% -7.88% -6.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $25.73M $26.28M $28.52M
YoY Change -7.9% -7.88% -6.6%
TOTAL ASSETS
Total Short-Term Assets $40.91M $45.60M $25.77M
Total Long-Term Assets $25.73M $26.28M $28.52M
Total Assets $66.64M $71.88M $54.29M
YoY Change 35.33% 32.39% -30.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.061M $1.550M $1.455M
YoY Change 20.84% 6.53% -57.02%
Accrued Expenses $960.0K $912.0K $1.301M
YoY Change -32.49% -29.9% 1.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.021M $2.462M $2.756M
YoY Change -12.13% -10.67% -40.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.021M $2.462M $2.756M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.021M $2.462M $2.768M
YoY Change -12.4% -11.05% -40.92%
SHAREHOLDERS EQUITY
Retained Earnings -$255.6M -$249.4M -$226.5M
YoY Change 10.35% 10.1% 11.54%
Common Stock $320.1M $319.0M $278.4M
YoY Change 14.79% 14.58% 0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.62M $69.41M $51.52M
YoY Change
Total Liabilities & Shareholders Equity $66.64M $71.88M $54.29M
YoY Change 35.33% 32.39% -30.26%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$6.150M -$5.852M -$5.907M
YoY Change 21.76% -0.93% -35.32%
Depreciation, Depletion And Amortization $600.0K $600.0K $610.0K
YoY Change -3.23% -1.64% 110.34%
Cash From Operating Activities -$4.980M -$4.860M -$3.900M
YoY Change 24.81% 24.62% -53.96%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K -$30.00K -$50.00K
YoY Change 433.33% -40.0% -82.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$160.0K -$30.00K -$50.00K
YoY Change 433.33% -40.0% -82.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 280.0K 37.90M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.980M -4.860M -3.900M
Cash From Investing Activities -160.0K -30.00K -50.00K
Cash From Financing Activities 280.0K 37.90M 0.000
Net Change In Cash -4.860M 33.01M -3.950M
YoY Change 20.9% -935.7% -51.77%
FREE CASH FLOW
Cash From Operating Activities -$4.980M -$4.860M -$3.900M
Capital Expenditures -$160.0K -$30.00K -$50.00K
Free Cash Flow -$4.820M -$4.830M -$3.850M
YoY Change 21.72% 25.45% -52.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Amendment Flag
AmendmentFlag
false
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1550000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1653000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
912000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1291000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-216000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-255000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
486000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
638000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1056000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
748000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
486000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1056000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
747000
CY2019Q2 us-gaap Assets
Assets
71875000
CY2018Q4 us-gaap Assets
Assets
44345000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
45599000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17016000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44921000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15823000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31768000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24849000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
29098000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6919000
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Type
DocumentType
10-Q
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
xbit
dei Entity Central Index Key
EntityCentralIndexKey
0001626878
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41011485
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
XBiotech Inc.
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2019Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41003660
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35899772
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
319045000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
279353000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5951000
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5526000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11677000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9588000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div></div></div>
CY2019Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3000
us-gaap Depreciation
Depreciation
1199000
us-gaap Depreciation
Depreciation
1198000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
39000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
388000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71875000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
102000
CY2018Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-393000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-44000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-376000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1313000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1672000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2591000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2829000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q2 us-gaap Investment Income Net
InvestmentIncomeNet
107000
us-gaap Investment Income Net
InvestmentIncomeNet
129000
us-gaap Investment Income Net
InvestmentIncomeNet
170000
CY2019Q2 us-gaap Liabilities
Liabilities
2462000
CY2018Q4 us-gaap Liabilities
Liabilities
2947000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-212000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-275000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-379000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-515000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-647000
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
51000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44345000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2462000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2944000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38636000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
201000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9540000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7426000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5852000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5907000
us-gaap Net Income Loss
NetIncomeLoss
-11716000
us-gaap Net Income Loss
NetIncomeLoss
-9976000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
154000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-286000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
95000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-206000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6006000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
5621000
us-gaap Operating Expenses
OperatingExpenses
11811000
us-gaap Operating Expenses
OperatingExpenses
9770000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6006000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5621000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11811000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9770000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-99000
CY2018Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
381000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
387000
CY2019Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
CY2018Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
10000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82000
CY2019Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2018Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
678000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1193000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
837000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
401000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
939000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
26276000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27329000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4693000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3949000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9220000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6941000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249416000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237700000
us-gaap Share Based Compensation
ShareBasedCompensation
1056000
us-gaap Share Based Compensation
ShareBasedCompensation
747000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
168584
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
693500
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.56
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.53
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5535439
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5803827
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
161000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
256528
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
37497000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
37497000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
36983000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
69413000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
56410000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
51522000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
41398000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
60162000
CY2018Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
200000
CY2019Q2 xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
296000
xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
837000
xbit Common Stock Share Subscribed Value Issuance
CommonStockShareSubscribedValueIssuance
201000
xbit Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
37497000
xbit Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
302000
xbit Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
201000
CY2019Q2 xbit Stock Issued During Period Value Collection Of Stock Subscription
StockIssuedDuringPeriodValueCollectionOfStockSubscription
102000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div></div>
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37519697
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35819772
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36752820
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35783738
xbit Stock Issued During Period Value Collection Of Stock Subscription
StockIssuedDuringPeriodValueCollectionOfStockSubscription
302000

Files In Submission

Name View Source Status
0001171843-19-005378-index-headers.html Edgar Link pending
0001171843-19-005378-index.html Edgar Link pending
0001171843-19-005378.txt Edgar Link pending
0001171843-19-005378-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_080919p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20190630.xml Edgar Link completed
xbit-20190630.xsd Edgar Link pending
xbit-20190630_cal.xml Edgar Link unprocessable
xbit-20190630_def.xml Edgar Link unprocessable
xbit-20190630_lab.xml Edgar Link unprocessable
xbit-20190630_pre.xml Edgar Link unprocessable